Pages 6, 7, 9, 10: Nice descriptions of their mechanisms of action, modulated pathways and relevant diseases. But my favoriet is on page 19, Mechanism of Action: "RVX-208 mediated inhibition affects multiple processes important for CVD. In addition to effects on lipoproteins, RVX-208 represses pathways underlying the pathogenesis of atherosclerosis and acute coronary events, including inflammation, complement, coagulation (thrombosis) and atherogenesis. Based on mechanistic data, we believe that RVX-208 treatment, or select BET inhibition, attenuates the inflammatory process that contributes to disease initiation and progression. Furthermore, we hypothesize that RVX-208 treatment restores basal activity of the inflammatory and innate immune response and clotting cascade with immediate benefits to atherosclerosis and cardiovascular disease. This is consistent with observed reductions in MACE, especially in patients with an acute inflammatory component in CVD."

Pages 11-12: Discussion of relevance of RVX-208 to Diabetes, Chronic Kidney Disease and Neurodegenerative Disease

Page 7: The Regulatory Process for Drug Development "New Drug Application (“NDA”) or Marketing Authorisation Application (“MAA”): Upon completion of Phase 3 Clinical Trials, the company sponsoring the new drug then assembles all the preclinical and clinical data and submits it to the TPD and/or the FDA as part of a NDA in the United States, an MAA in Europe or a New Drug Submission (“NDS”) in Canada. The NDA, MAA or NDS is then reviewed by the regulatory body for approval to market the product. This process usually takes between one and two years to complete with the exception of evaluations of breakthrough products in only 6 months."

Later on page 19, Regulatory Matters: "Recent meetings with health authorities in Germany, Sweden and UK have provided scientific advice to help design a Phase 3 study to support filing an MAA within Europe. The scientific advice has been incorporated into the Phase 3 RVX-208 BETonMACE clinical study which is scheduled to commence recruitment in the fall of 2015.Discussions with FDA on the design of additional future studies are currently ongoing." This last sentence leaves me wondering if BETonMACE will launch in the Fall with future FDA approval still pending.

On pages 12-13 "Competitive Environment:, they have a table listing competitor drugs. It is interesting the in the column for "indication", they list RVX-208 as "secondary MACE reduction" but all others as "CVD." This is relevant to Koo's comment earlier. I'm a little confused as to why they list secondary MACE reduction but not CVD. They seem the same to me.

On page 14, in regards to Pooled Mace Analysist the numbers here a a little different than those I wrote about earlier today, possible because its listed as cumulative MACE events as opposed to % of patient with MACE. I think the % of patients with MACE had a 3.9% vs 13.8% split for the diabetic population. The cumulative numbers are even more impressive: "Results from an additional high risk patient population, those with diabetes mellitus were reported September 2, 2014. In this analysis, patients treated with RVX-208 (n=127) had less cumulative events of 4.71% vs. 20.31% (p=0.008) in the placebo treated group (n=65). These early pooled analyses on MACE are also being examined in other high risk populations within both SUSTAIN and ASSURE patients such as CKD patients. A similar trend was observed in these patients as well. We will continue to utilize this important information to further determine the best path moving forward for future clinical development of RVX-208."

Page 14: Statement on BETonMACE. Once again, mentions comparing atorvastatin to rosuvastatin with 250 MACE events as a goal. Also, table on page 18 lists "Enrolling Fall 2015" as status. Minimum patients here listed as 2400, consistent with the 2400-4800 range listed in the MD&A document. "Phase 3 BETonMACE – Secondary Prevention Trial – Planned to Commence in 2015. Our intention is to reconfirm in a larger prospective setting with patients that have modifiable vascular disease (i.e. low HDL-C and diabetes) positive effects on markers of vascular risk and reduction of MACE. The proposed study is a large multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial in high-risk Type II Diabetes patients with CAD to determine whether treatment with RVX-208 in combination with rosuvastatin and atorvastatin increases the time to major adverse cardiovascular events compared to treatment with rosuvastatin and atorvastatin alone. The study is an event-based trial and will continue until a minimum of 250 primary endpoint events have occurred. We anticipate that no fewer than 2,400 patients will be enrolled. "

Page 19, Intellectual Property, "As of July 27, 2015, we own and/or have rights to numerous patent families, comprising ten issued US patents and a number of pending applications. This includes non-provisional US and provisional applications. The pending patent applications are largely interrelated and assert rights to substantially similar inventions in different jurisdictions. In fiscal 2012, Resverlogix was granted four patents, including a United States Patent covering composition of matter claims to RVX-208, and a United States Patent covering the manufacturing of RVX-208. In fiscal 2013, Resverlogix was granted seven patents including a United States Patent related to inflammatory diseases. In fiscal 2014, Resverlogix was granted eleven patents, including a patent in Europe containing composition of matter claims to RVX-208. In fiscal 2015, Resverlogix was granted eighteen patents including United States patents related to use claims for RVX-208 and manufacturing of RVX-208."

Pages 38-39: Clinical Steering Committee for BETonMACE: Big names.....including Stephen Nicholls, Harry Ginsberg, Peter Toth, Gregory Schwartz, Kausik Ray